Minoxidil: a comprehensive review
Topical minoxidil (5% foam, 5% solution, and 2% solution) is FDA-approved for androgenetic alopecia (AGA) in men and women. Mechanism of action: Minoxidil acts through multiple pathways (vasodilator, anti-inflammatory agent, inducer of the Wnt/β-catenin signaling pathway, an antiandrogen), and may a...
Main Authors: | A. K. Gupta, M. Talukder, M. Venkataraman, M. A. Bamimore |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-05-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2021.1945527 |
Similar Items
-
Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring
by: Reese Imhof, MD, et al.
Published: (2023-12-01) -
Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia
by: Aditya K. Gupta, et al.
Published: (2022-10-01) -
Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride
by: B S Chandrashekar, et al.
Published: (2015-01-01) -
New Target for Minoxidil in the Treatment of Androgenetic Alopecia
by: Shen Y, et al.
Published: (2023-08-01) -
Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia
by: Zari Shadi
Published: (2023-04-01)